Mednet Logo
CommunityHematology

How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?

Community PollStarted

What treatment would you offer a patient >70 years old with relapsed transformed DLBCL who received prior R-CHOP and bendamustine + obinutuzumab?

61 physicians have voted

Join Mednetto vote and see how they answered.

9 Answers
Mednet Member
Mednet MemberInvited Expert
Hematology · USC Keck School of Medicine
Answered on

I would give tafasatimab and Revlimid per the L-MIND study. I have been so impressed by this well tolerated immunotherapy regimen and the durability of responses. Literally, it looks competitive with car T cell therapy. Car, T cells would be an option, if the patient is very fit for their age and th...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Lurie Comp Cancer Center of Northwestern Univ
Answered on

If the goal is palliation then Tafasitamab + lenalidomide or bi-specifics. If the goal is cure and the patient is reasonably fit, then CAR T.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on

It's a tough question, as there's no single standard of care approach here, especially because the patient-specific details really matter here. Options basically boil down to whether the patient is felt to benefit more from a cytotoxic approach or from a T-cell engaging approach. Approaches could be...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Jacksonville
Answered on

Interesting case. In a similar case, I gave R-GCVP and achieved long remission. However, it depends on the time interval between prior regimens. If it was short, I’d probably do something like Len-Rituximab or Len-Tafa and justify the patient is transplant-ineligible.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Maryland Cancer Center
Answered on

I would test his candidacy for CD19 CAR-T with Liso-Cel and if eligible, I would offer it to him. The PILOT study (Sehgal et al., PMID 35839786) showed that the transplant-ineligible population (including those age 70 and above) achieved an ORR of 80% (54% CR) and those achieving CR have a long dura...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · NYU Winthrop Hospital
Answered on

Taftasimab and lenalidomide: well tolerated in elderly patients, good remission.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Riverside Methodist Hospitals/OhioHealth
Answered on

It really depends on the patient's functional status. If healthy/fit, I would treat with CAR-T. If borderline health/fitness, I would treat with tafasitamab and Revlimid.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology
Answered on

I would defer ASCT eligibility to the transplant physician. Personally, this patient's disease appears chemo-refractory.

He is an ideal candidate for liso-cel (or axi-cel, depending on the closest center performing CAR-T), provided he checks all the required boxes for eligibility for CAR-T.

I'd be c...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Hematology · University of California Irvine
Answered on

I think it might depend on how long ago the prior chemotherapies were. If relatively remote, some kind of "salvage" (Pola-BR?) then auto transplant would be reasonable. I know this is transformation but if the chemo was relatively recent, I probably would try to get that person to CAR-T ASAP if an o...

Join for free or sign in to see the full answer